Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01114308 · ClinicalTrials.gov registry record · Phase 3
A Six-Month Randomized Controlled Trial (RCT) of Probuphine Safety and Efficacy in Opioid Addiction
A Phase 3 study, sponsored by Titan Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 287
- Enrollment target
NCT01114308 is a Phase 3 study that has completed, run by Titan Pharmaceuticals. The registered enrollment target is 287 participants.
The verdict
NCT01114308, a Phase 3 study, has completed, sponsored by Titan Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 287 participants
- Enrollment target
Study Summary
Probuphine (buprenorphine implant) is an implant placed just below the skin containing buprenorphine (BPN). BPN is an approved treatment for opioid dependence. This study will confirm the efficacy of Probuphine vs. placebo and compare Probuphine treatment verses treatment with sublingual buprenorphine in the treatment of patients with opioid dependence.
Interventions
- DRUG Buprenorphine
- DRUG Probuphine (buprenorphine implant)
- DRUG placebo implant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 287 participants |
| Start Date | 2010-04 |
| Est. Completion | 2011-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01114308
The ClinicalTrials.gov registry entry for NCT01114308 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 287 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Titan Pharmaceuticals, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Buprenorphine is the first listed.
NCT01114308 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01114308 about?
NCT01114308 is a clinical study titled "A Six-Month Randomized Controlled Trial (RCT) of Probuphine Safety and Efficacy in Opioid Addiction". Probuphine (buprenorphine implant) is an implant placed just below the skin containing buprenorphine (BPN). BPN is an approved treatment for opioid dependence. This study will confirm the efficacy of Probuphine vs. placebo and compare Probuphine treatment verses treatment with sublingual buprenorphi...
What is the current status of trial NCT01114308?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 287 participants. The study started on 2010-04. Estimated completion is 2011-05.
What interventions are being tested in trial NCT01114308?
The interventions under investigation include: Buprenorphine (DRUG), Probuphine (buprenorphine implant) (DRUG), placebo implant (DRUG).
Who is sponsoring clinical trial NCT01114308?
This trial is sponsored by Titan Pharmaceuticals, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.